https://www.pharmaradar360.com/article/aa289843a0d73452Pharma Surgeen2026-06-05T10:34:03.000ZΑνάκληση παρτίδων του προϊόντος MANUSHIELD CLEANERhttps://www.pharmaradar360.com/article/b425c952d23be09ePharma Surgeen2026-06-05T09:00:00.000Z「第163期 定時株主総会招集ご通知」の一部訂正についてを掲載しましたhttps://www.pharmaradar360.com/article/dd1a263bf8e3bfbePharma Surgeen2026-06-05T08:35:12.000Z«Ανάκληση παρτίδας του κτηνιατρικού φαρμακευτικού προϊόντος NICILAN TAB (40+10) MG/TAB», Κωδικός ΕΟΦ 0221701https://www.pharmaradar360.com/article/c67f18ccb692c21dPharma Surgeen2026-06-05T07:00:00.000ZOtsuka Establishes "Heatstroke Countermeasure Industry-Government-Academia Consortium" with the National Institute for Environmental Studies and Other Partnershttps://www.pharmaradar360.com/article/d17770fc4cc57af9Pharma Surgeen2026-06-05T06:20:20.000ZDriven by patients, delivering on our strategy: 2025 Integrated Annual Report now availablehttps://www.pharmaradar360.com/article/3b66e33089442c75Pharma Surgeen2026-06-05T06:01:38.000ZOversubscribed Strategic Equity Fundraise of £9 millionhttps://www.pharmaradar360.com/article/9405a16d057e9e73Pharma Surgeen2026-06-05T03:00:00.000Z[ANZEN]Revisions of PRECAUTIONS: Donanemab(genetical recombination) , etc. postedhttps://www.pharmaradar360.com/article/8034e21d3354e011Pharma Surgeen2026-06-05T03:00:00.000Z[SHINSA]Software as a Medical Device (SaMD) page updatedhttps://www.pharmaradar360.com/article/dd6dacb705969455Pharma Surgeen2026-06-05T00:00:00.000ZOtsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT (sibeprenlimab-szsi) Preserved Kidney Function Over 12 Months in IgA Nephropathy (IgAN)https://www.pharmaradar360.com/article/9eb74d659121e567Pharma Surgeen2026-06-05T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/68a392e42ac28065Pharma Surgeen2026-06-05T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/6bf0290e82b18a0cPharma Surgeen2026-06-05T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/e2ff6d91cea4cb75Pharma Surgeen2026-06-05T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/736d59421151eac0Pharma Surgeen2026-06-05T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/861043dd0b207c33Pharma Surgeen2026-06-05T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/bc80dbe63718886cPharma Surgeen2026-06-05T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/8fc60db17306da89Pharma Surgeen2026-06-05T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/1ad76307c65a1802Pharma Surgeen2026-06-05T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/6d851c30c65c3191Pharma Surgeen2026-06-05T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/9920d9d2950713ecPharma Surgeen2026-06-05T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/9efc457d367fa387Pharma Surgeen2026-06-05T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/8acb6344d1b9efe4Pharma Surgeen2026-06-05T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/008217d94ed9dbabPharma Surgeen2026-06-05T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/3b9b9e884ea6d617Pharma Surgeen2026-06-04T23:16:20.000ZMerck Animal Health Reinforces Commitment to Help Protect U.S. Livestock from New World Screwworm Threathttps://www.pharmaradar360.com/article/c8cab7ccc6968579Pharma Surgeen2026-06-04T22:38:46.000ZThe CEO Who Wants to Make Tacrolimus Historyhttps://www.pharmaradar360.com/article/820698e6066fc502Pharma Surgeen2026-06-04T18:49:01.000ZABPI comment on BGMA proposals for a new Voluntary Schemehttps://www.pharmaradar360.com/article/c1d196b3537dd0c4Pharma Surgeen2026-06-04T18:44:30.000ZAccelerated review of VPAG concludes without agreementhttps://www.pharmaradar360.com/article/a4e183c0612cc1adPharma Surgeen2026-06-04T18:38:48.000ZTime to emphasise the economics in health economicshttps://www.pharmaradar360.com/article/5bdb0986511ccc2fPharma Surgeen2026-06-04T16:00:00.000ZInnovent submits NDA for CLDN18.2 ADC for gastric cancerhttps://www.pharmaradar360.com/article/185dbce6f015922bPharma Surgeen2026-06-04T13:58:31.000ZLa AEMPS impulsa una sesión informativa sobre RECOPS, la nueva aplicación para el registro de comercialización de productos sanitarioshttps://www.pharmaradar360.com/article/e9d41dfa95c2ae88Pharma Surgeen2026-06-04T13:56:10.000ZSesión informativa sobre RECOPS, la nueva aplicación para el registro de comercialización de productos sanitarioshttps://www.pharmaradar360.com/article/8d15d994e3bd5804Pharma Surgeen2026-06-04T13:32:00.000ZResearch: MHRA Public Sector Equality Duty Report 2025-2026https://www.pharmaradar360.com/article/4d4eedc5c814c6e2Pharma Surgeen2026-06-04T12:00:00.000ZAmneal Announces U.S. FDA Approval of Romidepsin Injection Solutionhttps://www.pharmaradar360.com/article/37dc74d9712b0dcdPharma Surgeen2026-06-04T11:03:13.000ZStopping Cancer Before It Starts in Lynch Syndromehttps://www.pharmaradar360.com/article/f73f0b609f6b3d44Pharma Surgeen2026-06-04T10:56:55.000ZTaking control: Inspiring others to beat rare diseaseshttps://www.pharmaradar360.com/article/ecc4d4618204356ePharma Surgeen2026-06-04T10:54:56.000ZPaul van Geest presents Erasmus University research to Pope Leo XIV in Romehttps://www.pharmaradar360.com/article/fcd8ecf60054a397Pharma Surgeen2026-06-04T10:45:50.000ZMedicine levy makes the UK un-investable, say pharma leadershttps://www.pharmaradar360.com/article/6e1c6e168dd16e4fPharma Surgeen2026-06-04T10:34:03.000ZTeviot joins Pride Edinburgh celebrationshttps://www.pharmaradar360.com/article/08fbad1366deb8d4Pharma Surgeen2026-06-04T10:32:18.000ZCome on England! Fans urged to register their organ donation decision during the World Cuphttps://www.pharmaradar360.com/article/8a35d4e112d8bb5fPharma Surgeen2026-06-04T10:30:04.000ZDigital Health Coffee Time Briefing ☕https://www.pharmaradar360.com/article/57e56d16f5bf0f31Pharma Surgeen2026-06-04T10:19:17.000Z医薬品・医療機器等安全性情報 No.429（厚生労働省）https://www.pharmaradar360.com/article/227fce387363a048Pharma Surgeen2026-06-04T10:01:58.000ZNew wave of harm reduction specialists graduate as life-saving programme expands across Greater Glasgow and Clydehttps://www.pharmaradar360.com/article/1a2290fc8ef81437Pharma Surgeen2026-06-04T10:00:30.000ZClass 4 Medicines Defect Notification: Teva UK Ltd, Ponlimsi (Denosumab) 60mg Solution for Injection in Pre-filled Syringe, EL(26)A/27https://www.pharmaradar360.com/article/703172fdb4940001Pharma Surgeen2026-06-04T10:00:00.000ZWhat’s Trending in Oncology? A Discussion Following ASCO 2026 with Anne Marie Robertson from EVERSANAhttps://www.pharmaradar360.com/article/58f0e186d4ab3e4aPharma Surgeen2026-06-04T09:52:07.000ZUniversité Paris Cité, the Île-de-France Region, the City of Paris and LVMH lay the foundation stone of the Interdisciplinary Institute for Women’s Health (iWISH)https://www.pharmaradar360.com/article/2be104594c2f66c9Pharma Surgeen2026-06-04T09:51:02.000ZEMA and AMA collaborate on Ebola trials amid public health emergencyhttps://www.pharmaradar360.com/article/b54fa34c5af76511Pharma Surgeen2026-06-04T09:47:25.000ZSoftware documentation audits after QMSR | Greenlight Guruhttps://www.pharmaradar360.com/article/b18931cfcc532fcfPharma Surgeen2026-06-04T09:44:36.000ZEli Lilly continues genetic medicine push with $1.9bn Ascidian partnershiphttps://www.pharmaradar360.com/article/0fe31bf714e3d8f8Pharma Surgeen2026-06-04T09:43:12.000ZInternationalisation at home: why get started?https://www.pharmaradar360.com/article/62a8b14065a54d5aPharma Surgeen2026-06-04T09:32:07.000ZMassive Bio and Optellum partner on early NSCLC detection and trialshttps://www.pharmaradar360.com/article/3e11cadaa665c564Pharma Surgeen2026-06-04T09:28:43.000ZCellares and TScan to assess automated manufacturing of TSC-101 therapyhttps://www.pharmaradar360.com/article/63f1ccef4c60c5ecPharma Surgeen2026-06-04T09:02:49.000ZCardiopatie: il convegno in Humanitashttps://www.pharmaradar360.com/article/fab01b1e5057dfa6Pharma Surgeen2026-06-04T09:00:11.000Z医学イノベーション研究所（SiRIUS）の小林 天美講師が「第5回羽ばたく女性研究者賞（マリア・スクウォドフスカ＝キュリー賞）」の奨励賞を受賞しましたhttps://www.pharmaradar360.com/article/5980ff1cb8d2604fPharma Surgeen2026-06-04T08:56:00.000ZDengue Vaccine Shows Favourable Safety Profile in Travellers from Non-Endemic Regionshttps://www.pharmaradar360.com/article/cd020fc6eea968b6Pharma Surgeen2026-06-04T08:49:39.000ZObésité : les disparités s'accentuent entre pays développés et en développementhttps://www.pharmaradar360.com/article/9ea21cb28e6ea8a1Pharma Surgeen2026-06-04T08:31:00.000ZMore premature births due to the heat. What can we do?https://www.pharmaradar360.com/article/f16dc26327f136ddPharma Surgeen2026-06-04T08:28:55.000ZAME และ AME Group ได้รับตราสัญลักษณ์มาตรฐานไมซ์ในงาน MICE Standards Day 2026https://www.pharmaradar360.com/article/b5f3da99ff8ceb35Pharma Surgeen2026-06-04T08:27:01.000ZJ&J’s nipocalimab meets primary endpoint in Phase II JASMINE studyhttps://www.pharmaradar360.com/article/af510242741fcf1fPharma Surgeen2026-06-04T08:24:59.000ZLa cardiologie des HUS rayonne à l’internationalhttps://www.pharmaradar360.com/article/a0c26a07d3f47279Pharma Surgeen2026-06-04T08:21:36.000ZRegeneron and CytomX extend cancer therapy partnership to $4bn dealhttps://www.pharmaradar360.com/article/37cffcefd2433d89Pharma Surgeen2026-06-04T08:09:39.000ZPrivate equity firm invests in radiology services provider RadX Inc.https://www.pharmaradar360.com/article/25eb7532fb46984dPharma Surgeen2026-06-04T08:00:01.000ZRadNet seeks to secure $200M term loan to fuel expansionhttps://www.pharmaradar360.com/article/7b8ef20995be99b4Pharma Surgeen2026-06-04T07:46:22.000ZPrivate equity firm acquires Heritage Imaginghttps://www.pharmaradar360.com/article/f5f5a0d988987c8aPharma Surgeen2026-06-04T07:43:38.000ZLe Leem dévoile son Plan Compétences Biotech 2030 à l’occasion de la JNBB 2026https://www.pharmaradar360.com/article/a5d6522a529d437fPharma Surgeen2026-06-04T07:30:45.000ZLa AEMPS refuerza el control del mercado de productos cosméticos con cerca de 2.000 actuaciones en 2025https://www.pharmaradar360.com/article/13a8c340544bd476Pharma Surgeen2026-06-04T07:00:00.000Z‘What if that could be me?’https://www.pharmaradar360.com/article/f2ed0736aab25a8aPharma Surgeen2026-06-04T07:00:00.000ZTeresa Macarulla and Tian Tian lead the new IDIBAPS research group 'Translational oncology in upper gastrointestinal cancers'https://www.pharmaradar360.com/article/592b4d89a1e4f65dPharma Surgeen2026-06-04T06:58:00.000ZThree to join Interim Chancellor Davies at June 8 forumhttps://www.pharmaradar360.com/article/ed2696c934991dd5Pharma Surgeen2026-06-04T06:56:00.000ZHealing Arts Program launches first staff art exhibitionhttps://www.pharmaradar360.com/article/bd554083d96a1e69Pharma Surgeen2026-06-04T06:54:00.000ZNicki Simmons retires from CAHP after 30 yearshttps://www.pharmaradar360.com/article/d7b04de0e54cbf8aPharma Surgeen2026-06-04T06:50:00.000ZBox verification system changing at 6 p.m. todayhttps://www.pharmaradar360.com/article/a7e3441cfcfa14d3Pharma Surgeen2026-06-04T06:35:50.000ZOCULOTECT 50 mg/ml COLIRIO EN SOLUCION , 1 frasco de 10 ml (NR: 61982, CN: 755215)https://www.pharmaradar360.com/article/ed344081aa5a4570Pharma Surgeen2026-06-04T06:33:23.000ZVGR växlar upp i Almedalen – tre publika panelsamtalhttps://www.pharmaradar360.com/article/484e18661669d40cPharma Surgeen2026-06-04T06:31:55.000ZEvents in Junehttps://www.pharmaradar360.com/article/dea2964dd05f530dPharma Surgeen2026-06-04T06:30:55.000ZJohn Browett named chair of NHS online hospital trusthttps://www.pharmaradar360.com/article/c660bd4ae358f0b1Pharma Surgeen2026-06-04T06:24:22.000ZBispecific and multi-specific antibody development journey at WuXi Biologicshttps://www.pharmaradar360.com/article/ee8946d67756410aPharma Surgeen2026-06-04T06:00:00.000ZLe mystère des poissons devenus aveugleshttps://www.pharmaradar360.com/article/bbfa8b4f26c30c53Pharma Surgeen2026-06-04T05:30:22.000ZCancer’s favorite escape trick may actually make it easier to killhttps://www.pharmaradar360.com/article/69d3c0547ad07b09Pharma Surgeen2026-06-04T05:01:40.000ZFederation Plus Fine Tuning: The Push for Federated Learning Models Continueshttps://www.pharmaradar360.com/article/02942e36485a469bPharma Surgeen2026-06-04T05:00:00.000ZNorthwest Arkansas Pathology Associates adopts Techcyte Fusion® AP to enable remote pathology and address workforce shortageshttps://www.pharmaradar360.com/article/fa94eb9a008da98bPharma Surgeen2026-06-04T04:16:06.000Z「美味しいサプリ」をグミで。少量生産を実現する新ソリューション「グミ ミニ・プラント」販売開始https://www.pharmaradar360.com/article/f970841bb7f6b396Pharma Surgeen2026-06-04T04:13:00.000ZAlnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneerhttps://www.pharmaradar360.com/article/6811cfe4e486ffc8Pharma Surgeen2026-06-04T03:15:23.000Z【日本医学会】第10回研究倫理教育研修会「医学・医療と共に進化する研究倫理」収録映像公開のご案内https://www.pharmaradar360.com/article/e4c14047ed2b745bPharma Surgeen2026-06-04T03:00:00.000Z[IBENTO][IBENTO]Report on the PMDA-ATC 10th Anniversary Ceremony has been posted.https://www.pharmaradar360.com/article/5fa195e70e962aa6Pharma Surgeen2026-06-04T03:00:00.000Z[SHINSA]English Translation of Review Report: Doptelet (Partial Change Approval)https://www.pharmaradar360.com/article/eff3a58e129481fbPharma Surgeen2026-06-04T03:00:00.000Z[SHINSA]English-language Early Considerations 'Considerations for the General Toxicity Evaluation of Monoclonal Antibodies （Early Consideration）' has been published.https://www.pharmaradar360.com/article/c92ae3558119cc6fPharma Surgeen2026-06-04T02:00:00.000ZPremio Innovazione Digitale in Sanità 2026, anche il Policlinico di Milano tra i vincitorihttps://www.pharmaradar360.com/article/9ca521d4d334e8ebPharma Surgeen2026-06-04T01:57:47.000Z抗悪性腫瘍経口黄体ホルモン製剤「ヒスロンH錠200mg」の限定出荷に関するお詫びとお知らせ_第2報（協和キリン株式会社）https://www.pharmaradar360.com/article/6ceb532d6c57218aPharma Surgeen2026-06-04T00:54:30.000Z市民公開講座「難聴と誤嚥」を開催しましたhttps://www.pharmaradar360.com/article/ac77ea04bcbd6ad2Pharma Surgeen2026-06-04T00:00:00.000ZMenu — Petro's Chili & Chips™https://www.pharmaradar360.com/article/36e66203c0d2a791Pharma Surgeen2026-06-04T00:00:00.000ZIntrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trialhttps://www.pharmaradar360.com/article/534bb9b520c0a116Pharma Surgeen2026-06-04T00:00:00.000ZBacterial engineering for cancer therapyhttps://www.pharmaradar360.com/article/a717be9aa7429e50Pharma Surgeen2026-06-04T00:00:00.000ZAberrant tau accumulation caused by MAPT mutations induces early pathological changes in axonal transport that are rescued by p38α inhibitionhttps://www.pharmaradar360.com/article/ae48c340949a8299Pharma Surgeen2026-06-04T00:00:00.000ZAAV gene therapy for homozygous familial hypercholesterolemia: a phase 1 trialhttps://www.pharmaradar360.com/article/da4f7fa27ece4773Pharma Surgeen2026-06-04T00:00:00.000ZSpinal cord stimulation for upper limb motor function in people with chronic post-stroke hemiparesis: a feasibility trialhttps://www.pharmaradar360.com/article/b90b9ea2c7cd356bPharma Surgeen2026-06-04T00:00:00.000ZA socially assistive robot to support mental wellbeing in LGBTQ+ young people at risk of self-harm: a randomized controlled trialhttps://www.pharmaradar360.com/article/8489ad36c945e820Pharma Surgeen2026-06-04T00:00:00.000ZHuman microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resiliencehttps://www.pharmaradar360.com/article/37f9e7c70e774b3bPharma Surgeen2026-06-04T00:00:00.000ZMarked for destructionhttps://www.pharmaradar360.com/article/912837976820fabbPharma Surgeen2026-06-04T00:00:00.000ZThis mysterious lung disease affects millions of people – a drug tested in mice shows promisehttps://www.pharmaradar360.com/article/1fdbc792758fb9faPharma Surgeen2026-06-04T00:00:00.000ZWhat’s behind China’s historically high counts of corresponding authors?https://www.pharmaradar360.com/article/413458cfb2d7ace7Pharma Surgeen2026-06-04T00:00:00.000ZCER under MEDDEV 2.7/1 Rev. 4 and EU MDR | Greenlight Guruhttps://www.pharmaradar360.com/article/2efe4287399a80acPharma Surgeen2026-06-04T00:00:00.000ZDrew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergieshttps://www.pharmaradar360.com/article/1de2f83cdf501d33Pharma Surgeen2026-06-04T00:00:00.000ZGH Research Announces Publication of Phase 2a Postpartum Depression Resultshttps://www.pharmaradar360.com/article/3c926190f334b9a9Pharma Surgeen2026-06-04T00:00:00.000ZRiskgränsvärden för njursjukdom bekräftas genom mer exakta mätningarhttps://www.pharmaradar360.com/article/090496c2262ea14dPharma Surgeen2026-06-04T00:00:00.000ZÖvervakning av hjärtrytm i mobilen kan spara vårdresurserhttps://www.pharmaradar360.com/article/6ee97200092b2a29Pharma Surgeen2026-06-04T00:00:00.000ZFilantropiskt stöd av familjen Savén stärker forskning om kolorektalcancerhttps://www.pharmaradar360.com/article/7ded023d5d5ec0f2Pharma Surgeen2026-06-04T00:00:00.000ZCan Pool Water Really Dry Out Skin and Hair?https://www.pharmaradar360.com/article/831e6395a4574996Pharma Surgeen2026-06-03T22:57:08.000ZFT839: A Multi-Antigen Targeting Off-the-Shelf Dual-CAR T Cell for the Treatment of Pathogenic B and T Cells in Autoimmune Diseaseshttps://www.pharmaradar360.com/article/b2c51a7c191a231ePharma Surgeen2026-06-03T22:55:21.000ZSafety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE: A Phase 1 Study Supporting Same-Day Dischargehttps://www.pharmaradar360.com/article/556016a12c4bc8b5Pharma Surgeen2026-06-03T21:06:21.000ZSNMMI unveils 2026 Image of the Yearhttps://www.pharmaradar360.com/article/c52fe069c74c309aPharma Surgeen2026-06-03T20:00:07.000ZPharmaceutical Executive Daily: New FDA Draft Guidance Targets Gene Therapy Submission Burdenhttps://www.pharmaradar360.com/article/de0e7a866048034fPharma Surgeen2026-06-03T19:42:21.000ZHuman Hookworm Engineered to Produce, Secrete Anti-Tetrodotoxin Antibody Into Preclinical Host Bloodstreamhttps://www.pharmaradar360.com/article/7a286b7bcf7cd849Pharma Surgeen2026-06-03T19:19:22.000ZMoving Trials Forward: Inside the Merck and WCG Partnership that Unblocks Bottlenecks and Empowers Siteshttps://www.pharmaradar360.com/article/c10a72d4abd3660dPharma Surgeen2026-06-03T19:07:50.000ZSmall Molecules to Big Partnership: Incyte, Genesis Expand AI Collaboration to $1B+https://www.pharmaradar360.com/article/00fae60a0b595d9ePharma Surgeen2026-06-03T19:00:07.000ZCellares and TScan Agree to Evaluate Automated Manufacturing TSC-101 for Patients with Hematologic Malignancieshttps://www.pharmaradar360.com/article/086e63dd1417a342Pharma Surgeen2026-06-03T18:54:24.000ZNew Antibiotic, Manikomycin, Acts on Novel Ribosomal Targethttps://www.pharmaradar360.com/article/df84f2a87bc6fa61Pharma Surgeen2026-06-03T18:47:32.000ZAI triage tool slashes breast cancer screening workloads by 77%https://www.pharmaradar360.com/article/2422784bc7ebcc25Pharma Surgeen2026-06-03T18:30:49.000ZNew nursing hireshttps://www.pharmaradar360.com/article/bc2cc2eed1cbc203Pharma Surgeen2026-06-03T18:09:38.000ZNORD Joins Coalition of 48 Patient Advocacy Organizations Expressing Concerns Over Coverage Loss Under Final CMS Medicaid Work Requirementhttps://www.pharmaradar360.com/article/0f43f51f45e01df8Pharma Surgeen2026-06-03T17:47:40.000ZAn End-to-End Approach to Specialty Patient Serviceshttps://www.pharmaradar360.com/article/ccc9831befd6d890Pharma Surgeen2026-06-03T17:36:27.000ZDermacyd lança campanha sobre intimidade e relaçõeshttps://www.pharmaradar360.com/article/115c1c66cc7aa5d1Pharma Surgeen2026-06-03T17:30:18.000ZGrupo EMS anuncia rebranding, apresenta nova arquitetura de marcas e se posiciona como potência do setor farmacêutico no Brasilhttps://www.pharmaradar360.com/article/2abc1edd69fcba11Pharma Surgeen2026-06-03T17:21:57.000ZFocus apps are failing neurodivergent minds, new research findshttps://www.pharmaradar360.com/article/842eb68a03c4557bPharma Surgeen2026-06-03T17:07:53.000ZTar Heel researchers share their work with chancellor on the coasthttps://www.pharmaradar360.com/article/93446856b3088314Pharma Surgeen2026-06-03T17:03:24.000ZGlobal COVID-19 Trackerhttps://www.pharmaradar360.com/article/dfb046437b00af6fPharma Surgeen2026-06-03T17:00:00.000ZDigital Collaboration in the Pharmaceutical Cold Chain: How CSafe Connects Data, Systems, and Stakeholdershttps://www.pharmaradar360.com/article/5dee9f487593548bPharma Surgeen2026-06-03T16:59:42.000Z33° Jornadas de Jóvenes Investigadores en Brasil (AUGM)https://www.pharmaradar360.com/article/5cc46fd39bdd3da6Pharma Surgeen2026-06-03T16:59:40.000ZIntelligence for the decisions that matter mosthttps://www.pharmaradar360.com/article/dbb248c0eba57c00Pharma Surgeen2026-06-03T16:59:20.000ZSAHPRA strengthens industry collaboration to improve access to safe medicineshttps://www.pharmaradar360.com/article/d4612f921be7372aPharma Surgeen2026-06-03T16:53:00.000ZCommonwealth Fund: 21% of adults experienced a coverage denial in the past yearhttps://www.pharmaradar360.com/article/a3b1817ef172d077Pharma Surgeen2026-06-03T16:40:06.000Z8 new topics added in latest ACR Appropriateness Criteria updatehttps://www.pharmaradar360.com/article/e2598798579b7c6aPharma Surgeen2026-06-03T16:39:26.000ZHow to value a biotechhttps://www.pharmaradar360.com/article/62ab48e8e82c55f7Pharma Surgeen2026-06-03T16:30:59.000ZFramework for Review of Clinical Research Involving AI: Advancing Ethical Oversight in Clinical Researchhttps://www.pharmaradar360.com/article/b64b030390c11dffPharma Surgeen2026-06-03T16:26:16.000ZEli Lilly to Deny 340B Drug Pricing Due to Claims-Data Policy: Reporthttps://www.pharmaradar360.com/article/3c0ef02b9be036c1Pharma Surgeen2026-06-03T16:07:10.000ZUFRJ instala Gabinete de Crise para atuação em situações de violência urbanahttps://www.pharmaradar360.com/article/771a20c121070ac9Pharma Surgeen2026-06-03T16:07:00.000ZNew FDA Draft Guidance Targets Gene Therapy Submission Burden by Allowing Use of Existing CMC and Scientific Knowledgehttps://www.pharmaradar360.com/article/d1fccbc31ee53b01Pharma Surgeen2026-06-03T16:00:52.000ZBioproduction Pivots from Centralized to Regional Supporthttps://www.pharmaradar360.com/article/8bacc24fcc3604e8Pharma Surgeen2026-06-03T16:00:51.000ZGentler Cell Separation Methods Gain Momentumhttps://www.pharmaradar360.com/article/d32fab7467d1c226Pharma Surgeen2026-06-03T16:00:46.000ZWeb App Helps Flag Antibodies Where Manufacturability Might Be an Issuehttps://www.pharmaradar360.com/article/f87b1a3d8a7774ebPharma Surgeen2026-06-03T16:00:40.000ZNIIMBL to Support Vector Production and AI-Ready Training Projectshttps://www.pharmaradar360.com/article/21f5cbcf95a9b9d1Pharma Surgeen2026-06-03T16:00:00.000ZRubio reopening door with Gavihttps://www.pharmaradar360.com/article/f02564f6604ae6b7Pharma Surgeen2026-06-03T15:50:24.000ZVisita de la Universidad china de Yanshan para fortalecer la cooperación internacionalhttps://www.pharmaradar360.com/article/0006887a926d1ffcPharma Surgeen2026-06-03T15:49:21.000ZTauber recorrió las obras del edificio Anexo de Derechohttps://www.pharmaradar360.com/article/d265f45ed41d332dPharma Surgeen2026-06-03T15:48:45.000ZTauber: “La Universidad tiene que estar donde más se la necesita”https://www.pharmaradar360.com/article/24b03665804f3dd9Pharma Surgeen2026-06-03T15:44:55.000ZOver 8,600 class of 2026 members will attend commencement ceremonies this monthhttps://www.pharmaradar360.com/article/e953c0e5029c58d7Pharma Surgeen2026-06-03T15:41:31.000ZCellCarta and Sonic Healthcare Establish Strategic Partnership to Commercialize Companion Diagnostics Through Lab Networkhttps://www.pharmaradar360.com/article/857193c1a5018856Pharma Surgeen2026-06-03T15:33:32.000ZISSUE NO. 49 — Nonclinical Toxicology Studies